by admin | January 8, 2026 | Latest news, Press Releases
Copenhagen, Denmark, 8 January 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces topline data from two studies evaluating AT7687, its first-in-class GIPR...
by admin | April 23, 2025 | Latest news, Press Releases
Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of...
by admin | April 2, 2025 | Latest news, Press Releases
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity With strong genetic and clinical validation, AT-7687 aims to...
by admin | January 8, 2025 | Latest news, Press Releases
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first in-class lead candidate, AT-7687 in obesity AT-7687 offers a...
by admin | December 4, 2024 | Latest news, Press Releases
Round led by Versant Ventures with participation from founding investor Novo Holdings and new investors SR One, Dawn Biopharma and Pictet Entering Phase I testing for next-generation weight loss therapy by antagonizing GIPR Antag Therapeutics, a next-generation...
